SYSTEMIC CYCLOSPORINE IN HIGH-RIS KERATOPLASTY - LONG-TERM RESULTS

Systemic cyclosporine (CSA) was given to 43 high-risk keratoplasty patients (vascularisation in three or four quadrants and >16 stromal vessels): 14 received CSA for 12 months (long CSA group) and 29 for a 4-6 month period (short CSA group), A group of 37 similar high-risk keratoplasty patients received no CSA (no CSA group), In the no CSA group 27 (73%) grafts had rejection episodes compared with 21 (48.8%) in the combined CSA group (p = 0.025), Rejection was reversed in only 23.3% of the no CSA group, compared with 50% and 87.5% in the short (p = 0.06) and long (p = 0.002) CSA groups respectively, Compared with the no CSA group, overall graft survival was better in both the short (p = 0.019) and long (p = 0.0056) CSA groups, This improvement resulted from both a reduction in the incidence, and an increase in the reversal rate, of rejection episodes. The improvement continued after stopping CSA, suggesting that some immunological privilege had been reestablished, Acuities of 20/40 or better were achieved by 44.8% and 50% of eyes in the short and long CSA groups respectively, compared with 13.5% of eyes in the no CSA group.